Abstract
Introduction
The antibacterial market is highly mature, yet there is a compelling need to
discover new antibacterials to combat the escalating threats of drug
resistance, the threats posed by new and reemerging pathogens, and
bioterrorism threats. In recent years, unmet medical needs and the advent of
genomics technologies renewed companies' interest concerning antibacterial
drug discovery. Smaller pharmaceutical companies and biotech companies have fi
lled the void created when big pharma abandoned the arena and are now
developing more than 80% of today' s emerging antibacterial agents.
Get the Answers You Need to Shape Your Strategy
- Some approaches to antibacterial drug development are more notable
advances than others. What approaches are these and which approaches should
produce drugs that command higher prices than conventional antibiotics?
- Several factors are driving today' s antibacterial drug discovery efforts.
What factors are most relevant to fi ghting pathogens in community settings?
What factors are most relevant to fi ghting pathogens in hospital settings?
- Although big pharma has largely abandoned the development of antibacterial
agents, it has maintained a stake in the antibacterial market through a
variety of marketing and sales alliances. Which current partnerships between
big pharma and smaller pharmaceutical companies show the greatest promise?
- Several antibacterial blockbusters were on the market in 2005, yet most
pharmaceutical companies had a sparse antibacterial drug portfolio. Which
company is an exception to the rule that the antibacterial drug portfolio of
big pharma companies typically is dominated by a blockbuster agent? What
lessons can be learned from this company' s strategy of developing several
moderately successful drugs?
- Despite fi nancial and regulatory hurdles impeding the development of
antibacterial agents, commercial opportunities to develop antibacterials that
are effective against drug-resistant pathogens, especially in hospital
settings, still remain. What are these opportunities? What incentives would
bring more players into antibacterial drug discovery and development?
Scope
- New approaches to discovering antibacterial agents: the relative
importance of genomics, novel antibodies, topical antibacterial agents, PDF
inhibitors, novel beta-lactams, peptides and peptide mimetics, fatty acid
biosynthesis inhibitors, and combination therapies.
- Business strategies: drug discovery, marketing and sales alliances, big
pharma' s out-licensing programs, mergers and acquisitions, and strategies for
niche markets.
- Company profi les: Oscient Pharmaceuticals, Cubist Pharmaceuticals,
Replidyne, Novexel.
- Outlook: commercial opportunity and diagnostic, regulatory, fi nancial,
and legislative incentives.
- Spectrum expert commentary: an award-winning researcher explains how
quorum sensing may shine light on a new path to novel antibacterial drug
development.
Companies and Organizations
- Abbott
- Abraxis BioScience
- Advanced Life Science
- Adventrx
- Affi nium
- Apotex
- Ariagen
- Astellas
- Aventis
- AstraZeneca
- Basilea
- Bayer AG
- Baxter
- Biolinerx
- Biosynexus
- Biovertis
- BioXell
- Bristol-Myers Squibb
- California Institute of
- Technology
- Cerexa
- Chiron
- Chiron Healthcare Ireland
- Cilag
- Crystal Genomics
- Cubist
- Daiichi-Sankyo
- Department of Defense
- Eisai
- Eli Lilly
- Elusys
- Forest Laboratories
- Genentech
- Genesoft
- Genome Therapeutics
- Genzyme
- GlaxoSmithKline
- Inhibitex
- Intercell
- InterMune
- Janus
- Johnson & Johnson
- Kalobios
- King
- Kirin
- LG Life Sciences
- Medarex
- MedImmune
- Meiji Seika Kaisha
- Menarini
- Merck
- Mpex
- Mylan Laboratories
- Nabriva
- National Institutes of
- Health
- Nektar Therapeutics
- NeuTec
- Nordic
- Novartis
- Novexel
- Novozyme
- Oragenics
- Ortho-McNeil
- Oscient
- Paratek
- Par Pharmaceutical
- Peninsula
- Pfi zer
- Prolysis
- Replidyne
- Roche
- Sanofi -Aventis
- Schering-Plough
- Shionigi
- Taisho
- Takeda
- Targanta
- Teijin
- Teva
- Theravance
- Toyama Chemical
- Tyco Healthcare
- United States Army
- Medical Research Institute
- of Infectious Diseases
- VaxGen
- Vicuron
- Wyeth
- XOMA
|
Related Report
|
View Cart
